• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Olympus launches EndoClot products for gastrointestinal procedures

Olympus launches EndoClot products for gastrointestinal procedures

April 21, 2023 By Sean Whooley

Olympus EndoClot spray and injection
[Image courtesy of Olympus]
Olympus announced the launch of its EndoClot offerings for use in gastrointestinal (GI) procedures in the Europe, Middle East and Africa (EMEA) region.

The EndoClot portfolio supports hemostasis and lifting in endoscopic submucosal dissection or resection in GI procedures. Olympus launched the EndoClot adhesive, the EndoClot polysaccharide hemostatic spray and the EndoClot submucosal injection solution.

EndoClot Plus developed the portfolio of GI solutions. The company expanded its distribution agreement with Olympus from the U.S. to EMEA in December 2022.

“We are excited to expand our global partnership with EndoClot Plus, Inc. The addition of their solutions to our portfolio allows us to strengthen our commitment to our customers as a full gastrointestinal solution provider for advanced therapeutic procedures,” said Stefanie Kaufung, EMEA business unit manager for GI endotherapy at Olympus. “Endoscopic resection and associated bleeding management are among Olympus’ core competencies. By contributing to safe treatment in gastrointestinal procedures, we aim to improve patient outcomes and hereby elevate the standard or care.”

About the Olympus EndoClot solutions

The EndoClot adhesive is a single-use medical device designed to seal lesions utilizing hemostatic polymer. This polymer offers durability thanks to its resistance to acids and bases in the GI tract. Its uses include at the end of a procedure to stop and control oozing bleeding. It may also prevent re-bleeding and protect the wound from irritation by acids and bases.

Olympus said the EndoClot polysaccharide hemostatic spray and submucosal injection solution utilize absorbable modified polymer (AMP) technology. This starch-derived AMP technology offers an excellent safety profile, according to the company.

EndoClot AMP particles absorb water from blood, causing a high concentration of platelets, red blood cells and coagulation proteins. This helps to accelerate the body’s clotting cascade. Olympus describes AMP particles as biocompatible, bioabsorbable, non-pyrogenic and starch-derived. They contain no animal or human components.

As of today, Olympus offers these EndoClot solutions commercially in Europe.

Filed Under: Blood Management, Business/Financial News, Surgical Tagged With: Olympus

More recent news

  • J&J delivers Shockwave data sustaining below-the-knee gains for two years
  • BD appoints worldwide president of Surgery business
  • Boston Scientific names COO amid cardiovascular restructuring
  • Getinge Life Science president is leaving
  • Endologix is now Rhevera Medical

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy